Skip to main content

Advertisement

SpringerLink
Log in

Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

We explored the associations between progression-free survival (PFS) after the initiation of PD-1 inhibitor therapy and the clinical parameters in patients with NSCLC. We reviewed the clinical data of patients with NSCLC treated with PD-1 inhibitor. Data of a total of 36 patients, including 16 patients with squamous cell NSCLC and 20 patients with non-squamous cell NSCLC were reviewed. Multivariate analyses identified EGFR status, C-reactive protein (CRP), and PFS following previous therapy as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy in patients with NSCLC. In patients with squamous cell NSCLC, the blood neutrophil/lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), serum C-reactive protein (CRP), and PFS following previous therapy were identified as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy. However, none of these associations, except for PFS following previous therapy, were found in patients with non-squamous cell NSCLC. NLR, LDH and CRP were associated with the PFS after initiation of PD-1 inhibitor therapy in patients with squamous cell NSCLC, and PFS following previous therapy was the common parameter associated with the PFS after initiation of PD-1 inhibitor therapy in both squamous-cell NSCLC and non-squamous-cell NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Article  CAS  Google Scholar 

  2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  Google Scholar 

  3. Taniguchi Y, Tamiya A, Isa SI, Nakahama K, Okishio K, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S (2017) Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res 37:5857–5862

    CAS  PubMed  Google Scholar 

  4. Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y (2017) Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 8:103117–103128

    Article  Google Scholar 

  5. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351–357

    Article  Google Scholar 

  6. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1–7

    Article  Google Scholar 

  7. Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T (2017) Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. Int J Clin Oncol 22(4):690–697

    Article  CAS  Google Scholar 

  8. Inomata M, Hayashi R, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Suzuki K, Yamada T, Miwa T, Kashii T, Matsui S, Tobe K (2014) Outcome and prognostic factors in patients with small cell lung cancer who receive third-line chemotherapy. Tumori 100:507–511

    Article  Google Scholar 

  9. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G (2009) Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation 32:169–175

    Article  CAS  Google Scholar 

  10. Lippitz BE, Harris RA (2016) Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology 5:e1093722

    Article  Google Scholar 

  11. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71:424–434

    Article  CAS  Google Scholar 

  12. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66:10517–10524

    Article  CAS  Google Scholar 

  13. Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B, Alkis N (2014) A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One 9:e114471

    Article  Google Scholar 

  14. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V et al (2003) Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89:877–885

    Article  CAS  Google Scholar 

  15. Danner BC, Didilis VN, Wiemeyer S, Stojanovic T, Kitz J, Emmert A, Füzesi L, Schöndube FA (2010) Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res 30:1347–1351

    CAS  PubMed  Google Scholar 

  16. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M (2006) Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107:2013–2021

    Article  CAS  Google Scholar 

  17. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812–3819

    Article  CAS  Google Scholar 

  18. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124

    Article  Google Scholar 

  19. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93–103

    Article  CAS  Google Scholar 

  20. Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134:230–234

    CAS  PubMed  Google Scholar 

  21. el-Hag A, Clark RA (1987) Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 139:2406–2413

    CAS  PubMed  Google Scholar 

  22. Hiramatsu S, Tanaka H, Nishimura J, Sakimura C, Tamura T, Toyokawa T, Muguruma K, Yashiro M, Hirakawa K, Ohira M (2018) Neutrophils in primary gastric tumors are correlated with neutrophil infiltration in tumor-draining lymph nodes and the systemic inflammatory response. BMC Immunol 19(13):16

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Toyama University Hospital, Sugitani 2630, Toyama City, 930-0194, Japan

    Minehiko Inomata, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Tomomi Ichikawa, Shingo Imanishi, Toru Yamada, Toshiro Miwa & Kazuyuki Tobe

  2. Department of Medical Oncology, Toyama University Hospital, Toyama City, Japan

    Ryuji Hayashi

Authors
  1. Minehiko Inomata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takahiro Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zenta Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kotaro Tokui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chihiro Taka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seisuke Okazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenta Kambara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tomomi Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shingo Imanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toru Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshiro Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ryuji Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuyuki Tobe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minehiko Inomata.

Ethics declarations

Conflict of Interest

None.

Financial Support

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inomata, M., Hirai, T., Seto, Z. et al. Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathol. Oncol. Res. 26, 327–333 (2020). https://doi.org/10.1007/s12253-018-0473-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-018-0473-x

Keywords

Search

Navigation